-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Clover Biopharmaceuticals, Ltd.'s (HKG:2197) Market Cap Surged HK$2.7b Last Week, Individual Investors Who Have a Lot Riding on the Company Were Rewarded
Clover Biopharmaceuticals, Ltd.'s (HKG:2197) Market Cap Surged HK$2.7b Last Week, Individual Investors Who Have a Lot Riding on the Company Were Rewarded
Every investor in Clover Biopharmaceuticals, Ltd. (HKG:2197) should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are individual investors with 29% ownership. Put another way, the group faces the maximum upside potential (or downside risk).
Clearly, individual investors benefitted the most after the company's market cap rose by HK$2.7b last week.
In the chart below, we zoom in on the different ownership groups of Clover Biopharmaceuticals.
View our latest analysis for Clover Biopharmaceuticals
SEHK:2197 Ownership Breakdown November 20th 2022What Does The Institutional Ownership Tell Us About Clover Biopharmaceuticals?
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
As you can see, institutional investors have a fair amount of stake in Clover Biopharmaceuticals. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Clover Biopharmaceuticals' historic earnings and revenue below, but keep in mind there's always more to the story.
SEHK:2197 Earnings and Revenue Growth November 20th 2022Clover Biopharmaceuticals is not owned by hedge funds. Because actions speak louder than words, we consider it a good sign when insiders own a significant stake in a company. In Clover Biopharmaceuticals' case, its Top Key Executive, Peng Liang, is the largest shareholder, holding 18% of shares outstanding. In comparison, the second and third largest shareholders hold about 15% and 7.8% of the stock. In addition, we found that Joshua G. Liang, the CEO has 1.6% of the shares allocated to their name.
On looking further, we found that 51% of the shares are owned by the top 5 shareholders. In other words, these shareholders have a meaningful say in the decisions of the company.
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.
Insider Ownership Of Clover Biopharmaceuticals
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
It seems insiders own a significant proportion of Clover Biopharmaceuticals, Ltd.. It has a market capitalization of just HK$6.0b, and insiders have HK$1.3b worth of shares in their own names. We would say this shows alignment with shareholders, but it is worth noting that the company is still quite small; some insiders may have founded the business. You can click here to see if those insiders have been buying or selling.
General Public Ownership
The general public-- including retail investors -- own 29% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
Private Equity Ownership
With a stake of 23%, private equity firms could influence the Clover Biopharmaceuticals board. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.
Private Company Ownership
Our data indicates that Private Companies hold 6.1%, of the company's shares. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.
Next Steps:
It's always worth thinking about the different groups who own shares in a company. But to understand Clover Biopharmaceuticals better, we need to consider many other factors. Be aware that Clover Biopharmaceuticals is showing 2 warning signs in our investment analysis , you should know about...
Ultimately the future is most important. You can access this free report on analyst forecasts for the company.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
每一位三葉草生物製藥有限公司(HKG:2197)的投資者都應該知道最強大的股東羣體。而持有這塊蛋糕最大份額的羣體是擁有29%股權的個人投資者。換句話説,該集團面臨着最大的上行潛力(或下行風險)。
顯然,在上週該公司市值上漲27億港元后,散户投資者受益最大。
在下面的圖表中,我們放大了三葉草生物製藥的不同所有權組。
查看我們對三葉草生物製藥的最新分析
聯交所:2197擁有權分類2022年11月20日關於三葉草生物製藥公司,機構所有權告訴了我們什麼?
許多機構以一個接近當地市場的指數來衡量它們的表現。因此,他們通常更關注那些被納入主要指數的公司。
正如你所看到的,機構投資者在三葉草生物製藥公司持有相當數量的股份。這意味着為這些機構工作的分析師已經看過了這隻股票,他們喜歡它。但就像其他人一樣,他們也可能錯了。當多家機構持有一隻股票時,它們總是面臨“擁擠交易”的風險。當這樣的交易出錯時,多方可能會競相快速拋售股票。在一家沒有增長曆史的公司,這一風險更高。你可以在下面看到三葉草生物製藥公司的歷史收益和收入,但請記住,故事總是有更多的內容。
聯交所:2197盈利及收入增長2022年11月20日三葉草生物製藥公司並非由對衝基金所有。由於行動勝於雄辯,我們認為,當內部人士持有一家公司的大量股份時,這是一個好跡象。在三葉草生物製藥公司的案例中,其最高高管彭亮是最大股東,持有18%的流通股。相比之下,第二大股東和第三大股東分別持有約15%和7.8%的股份。此外,我們發現,首席執行官樑朝偉有1.6%的股份分配給他們的名字。
進一步觀察,我們發現前五大股東持有51%的股份。換句話説,這些股東在公司的決策中擁有有意義的發言權。
研究機構持股是衡量和篩選股票預期表現的好方法。通過研究分析師的情緒,也可以達到同樣的效果。分析師對該股的報道不多,但也不多。因此,它有獲得更多報道的空間。
三葉草生物製藥的內部人所有權
不同國家對內部人的定義可能略有不同,但董事會成員總是算數的。公司管理層管理企業,但首席執行官將向董事會負責,即使他或她是董事會成員。
內部人持股是積極的,當它標誌着領導層像公司的真正所有者一樣思考時。然而,高內部人持股也可以給公司內部的一個小團體帶來巨大的權力。在某些情況下,這可能是負面的。
內部人士似乎擁有三葉草生物製藥有限公司相當大的比例。它的市值只有60億港元,內部人士以自己的名義持有價值13億港元的股票。我們會説,這表明了與股東的一致,但值得注意的是,該公司仍相當小;一些內部人士可能創建了這家企業。你可以點擊這裏,看看這些內部人士是一直在買入還是賣出。
一般公有制
包括散户投資者在內的普通公眾持有該公司29%的股份,因此不能輕易忽視。儘管這種規模的所有權可能不足以影響有利於他們的政策決定,但他們仍然可以對公司政策產生集體影響。
私募股權所有權
私募股權公司持有23%的股份,可能會影響克洛弗生物製藥公司的董事會。一些人可能會喜歡這樣,因為私人股本有時是讓管理層承擔責任的積極分子。但在其他時候,私募股權公司讓公司上市後,它們的股票都賣光了。
私營公司所有權
我們的數據顯示,私營公司持有該公司6.1%的股份。私營公司可能是關聯方。有時,內部人士通過持有一傢俬人公司來對上市公司感興趣,而不是以個人身份。雖然很難得出任何大致的中風結論,但值得注意的是,這是一個值得進一步研究的領域。
接下來的步驟:
擁有一家公司股票的不同集團總是值得考慮的。但為了更好地瞭解三葉草生物製藥公司,我們需要考慮許多其他因素。請注意,三葉草生物製藥公司正在展示我們的投資分析中的2個警告信號,你應該知道關於……
最終未來是最重要的。您可以訪問此免費分析師對該公司的預測報告。
注:本文中的數字是使用過去12個月的數據計算的,指的是截至財務報表日期的最後一個月的12個月期間。這可能與全年的年度報告數字不一致。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧